Komori
Delta-Fly Pharma (4598) · InitiativeRestatedLatest Share Issuance and Disposal (2026-07-22): "Advanced"

Recruiting personnel to support growth in the development portfolio

First written in FY2019. 3 of 7 entries say "Restated". Latest entry: 2026-07-22.

7entries
8years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2019 – FY2024-Q2RaisedFY2025-H12019: 120192020: 020202021: 120212022: 120222023: 120232024: 120242025: 020252026: 22026
Same theme, other companies
Strengthening R&D staffing and development capabilitiesA theme 51 companies write about · 0 as a headwind · 52 as a tailwind

The whole theme swung hardest in 2026: 3 of 34 companies on the "Worse" side.

31 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 51 companies compared. The sentences above are computed from all 51.
Full recordFilings, disclosures and news, newest first
  1. 2026-07-22AdvancedShare Issuance and Disposal

    「As changes, additions and progress in the development stages of the products and manufacturing processes are expected, we plan to strengthen the development structure by adding 1 person to the current research and development staff of 7 (approximately ¥15 million to be allocated), adding 1 person to the pharmaceutical development, manufacturing and quality control staff (approximately ¥15 million to be allocated), and adding approximately 1 overseas specialist outsourcing provider (approximately ¥10 million to be allocated).」

    In anticipation of progress in the development products and manufacturing processes, a specific policy was stated to increase research and development personnel, development, manufacturing and quality control personnel, and overseas outsourcing providers.
  2. FY2026RestatedAnnual report

    「しかしながら、上記のとおり、今後開発品の増加が見込まれるため、適切な人材確保を図っていく方針です。」

    開発品の増加を見込み、適切な人材確保を進める方針を再確認している。
  3. FY2025-H1RaisedAnnual report

    「④ 開発体制・管理体制の強化(報酬・人件費等)及び特許関連費用等(関連経費) 302 2024年11月~2026年3月期」

    新株予約権による調達資金の使途として、開発体制・管理体制の強化等に302百万円を2024年11月から2026年3月期まで充当する計画が示された。従前の166百万円から金額が拡大している。
  4. FY2024-Q2開発・管理体制強化の資金使途を明示Annual report

    「開発体制・管理体制の強化(報酬・人件費)及び特許関連費用等(経費)」

    第三者割当等による調達資金の使途として、開発体制・管理体制の強化に166百万円を2023年11月から2025年3月期に充当する計画が示された。
  5. FY2022RestatedAnnual report

    「しかしながら、上記の通り、今後開発品の増加が見込まれるため、適切な人材確保を図っていく方針です。」

    開発品の増加を見込み、適切な人材を確保する方針を再確認している。
  6. FY2021RestatedAnnual report

    「しかしながら、上記のとおり、今後開発品の増加が見込まれるため、適切な人材確保を図っていく方針です。」

    開発品の増加を見込み、適切な人材確保を進める方針を再確認している。
  7. FY2019First statedAnnual report

    「しかしながら、上記のとおり、今後開発品の増加が見込まれるため、適切な人材確保を図っていく方針です。」

    開発品の増加を見込み、適切な人材の確保を今後の課題・施策として掲げている。
Moved together

"Fundraising through the exercise of stock acquisition rights" moved the same way as this thread, in the same document, in 2 of its 7 moves.

2★1
  1. ★This thread
  2. 1Fundraising through the exercise of stock acquisition rights2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Delta-Fly Pharma yet. It last moved in the Share Issuance and Disposal of 2026-07-22: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.